Quick charity verification for Society For Translational Oncology Inc (EIN: 203186261)
Verdict: Society For Translational Oncology Inc appears trustworthy
88/100Mission Score
$946KRevenue
$1.5MAssets
2Red Flags
4Strengths
Red Flags
Significant year-over-year revenue volatility, with a drop from $1,410,812 in 2022 to $467,002 in 2023.
Expenses ($722,531) exceeded revenue ($467,002) in the most recent filing (202312), resulting in an operating deficit.
Strengths
Consistent reporting of 0% officer compensation, indicating efficient use of funds for mission-related activities.
Strong asset base ($1,476,634 current assets) provides financial stability despite revenue fluctuations.
History of significant surpluses in prior years (e.g., 2021 and 2022) demonstrates capacity for strong financial performance.
Low liabilities relative to assets, with liabilities at $118,825 in 2023 against assets of $1,525,997.
Spending Breakdown
How Society For Translational Oncology Inc allocates its funds across programs, administration, and fundraising.
85%
Program Spending
Healthy — majority goes to mission
10%
Admin Costs
Reasonable — admin costs in check
5%
Fundraising
Within typical range
How to read this: Well-run charities typically spend 75% or more on programs, keep admin under 25%, and fundraising under 15%. A high program ratio means more of every dollar goes directly to the mission.
How to Interpret This Report
What Red Flags Mean
Red flags are potential warning signs identified by AI analysis of IRS 990 filings. They may indicate issues like declining revenue, high executive pay relative to program spending, lack of transparency, or governance concerns. A single red flag does not necessarily mean an organization is untrustworthy, but multiple flags warrant further investigation before donating.
What Mission Score Measures
The Mission Score (0-100) evaluates how effectively a nonprofit fulfills its stated purpose. It combines multiple factors: program spending efficiency (how much goes to programs vs. overhead), financial health and sustainability, governance quality, transparency in reporting, and consistency of operations over time. A score of 70+ indicates strong alignment with the organization’s mission.
Using This Data for Donation Decisions
Use this report as one input in your decision. Look at the overall Mission Score for a quick assessment, review red flags and strengths for specific concerns, check the spending breakdown to see where money goes, and compare executive compensation to the organization’s size. Consider viewing the full transparency report for deeper analysis, and always verify tax-exempt status with the IRS before making large donations.
Frequently Asked Questions about Society For Translational Oncology Inc
Is Society For Translational Oncology Inc a legitimate charity?
Based on AI analysis of IRS 990 filings, Society For Translational Oncology Inc (EIN: 203186261) appears trustworthy. Mission Score: 88/100. 2 red flags identified, 4 strengths noted.
Is Society For Translational Oncology Inc a good charity to donate to?
Society For Translational Oncology Inc has a Mission Score of 88/100. Revenue: $946K. Assets: $1.5M. Review the full transparency report for detailed spending breakdown and executive compensation analysis.
What is the EIN for Society For Translational Oncology Inc?
The Employer Identification Number (EIN) for Society For Translational Oncology Inc is 203186261. This is the unique tax ID assigned by the IRS.
What is a Mission Score?
The Mission Score is a 0-100 rating that measures how effectively a nonprofit fulfills its stated mission. It factors in program spending efficiency, financial transparency, governance practices, and outcome reporting. Scores above 70 indicate strong mission alignment, 40-69 suggest mixed performance, and below 40 signals potential concerns.
How does Society For Translational Oncology Inc spend its money?
Society For Translational Oncology Inc allocates 85% to programs, 10% to administration, and 5% to fundraising. Healthy nonprofits typically spend 75%+ on programs.
How can I verify Society For Translational Oncology Inc's tax-exempt status?
You can verify Society For Translational Oncology Inc's tax-exempt status using EIN 203186261 on the IRS Tax Exempt Organization Search (TEOS) at apps.irs.gov/app/eos. You can also request copies of their Form 990 directly from the organization, as they are required by law to provide them upon request.
AI Transparency Report
The Society For Translational Oncology Inc demonstrates a generally sound financial position, with assets consistently exceeding liabilities across its filing history. While revenue has fluctuated significantly year-to-year, ranging from a low of $285,145 in 2020 to a high of $1,410,812 in 2022, the organization has managed to maintain a healthy asset base, currently at $1,476,634. The most recent filing (202312) shows expenses ($722,531) exceeding revenue ($467,002), resulting in a net loss for that period, which warrants monitoring. However, the prior two periods (202112 and 202212) showed strong surpluses, indicating a capacity for financial recovery.
The organization appears to be efficient in its spending, particularly given the consistent reporting of 0% officer compensation, suggesting that resources are directed towards its mission rather than executive salaries. The absence of officer compensation also contributes positively to its transparency. The fluctuating revenue and expenses are typical for project-based or grant-funded organizations, but consistent monitoring of the expense-to-revenue ratio is advisable to ensure long-term sustainability. Overall, the organization exhibits good financial health and a commitment to program spending, as evidenced by its compensation structure.
Transparency is high due to the readily available IRS 990 filings and the clear reporting of financial data, including the consistent disclosure of zero officer compensation. This level of detail allows for a clear understanding of the organization's financial operations. The organization's ability to manage significant revenue fluctuations while maintaining a strong asset base suggests prudent financial management.